OMER 19.67 Omeros Corp $OMER Hit a 52 week high of 20.06

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
OMER 19.67 Omeros Corp $OMER Hit a 52 week high of 20.06 Closing the day 09:45 at 19.67 -0.04 -0.20% With a day low of 19.59 and a total volume of 50,671.

OMER Recent Posts: http://investorshangout.com/Omeros-Corp-OMER-54977/

OMER Omeros Corp Recent Headline News

Molecular Biology Meets Finance: MLV's George Zavoico On Ebola's Silver Lining
Life Sciences Report - Seeking Alpha - Thu Nov 13, 6:59AM CST
A working knowledge of molecular biology is essential for a biotech investor, but it helps when someone with deep knowledge of science and medicine can bring understanding to the people who commit capital to growth ideas. George Zavoico of MLV &...
CERS: 4.46 (+0.27), AGEN: 2.99 (-0.02), NVAX: 5.31 (+0.07), ALXN: 193.45 (-0.24), PPHM: 1.46 (-0.01), THLD: 3.06 (-0.08), GSK: 45.70 (+0.08), OMER: 19.54 (-0.17)

Omeros (OMER) Catches Eye: Stock Jumps 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 7:30AM CST
Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise almost 9% on the day.
ABAX: 55.08 (+0.88), GWPH: 75.80 (+0.48), OSUR: 8.99 (-0.19), OMER: 19.54 (-0.17)

Omeros ups revenues 9% in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:27AM CST

OMER: 19.54 (-0.17)

Omeros (OMER) CEO Gregory Demopulos on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 10:15PM CST

OMER: 19.54 (-0.17)

Omeros posts 3Q loss
Automated Insights - Mon Nov 10, 5:48PM CST
SEATTLE (AP) _ Omeros Corporation (OMER) on Monday reported a loss of $18.3 million, or 54 cents per share, in its third quarter.
OMER: 19.54 (-0.17)

Omeros beats by $0.05
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:19PM CST

OMER: 19.54 (-0.17)

Omeros Corporation Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:02PM CST
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced recent highlights and developments as well as financial results for the third quarter of 2014, which include:
OMER: 19.54 (-0.17)

Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST

HK: 3.05 (unch), WWD: 50.70 (-0.53), LLNW: 2.70 (+0.01), FXEN: 2.64 (-0.05), RMTI: 11.14 (-0.10), CZR: 15.60 (+1.93), EGY: 7.10 (+0.07), ICUI: 84.05 (-0.68), ICEL: 7.53 (-0.14), SAAS: 8.77 (-0.03), DMD: 5.48 (-0.22), NPSP: 29.66 (+0.49), SCLN: 8.67 (unch), ATHX: 1.40 (-0.03), CMLS: 3.25 (-0.10), TC: 2.00 (-0.05), ATW: 34.64 (-0.88), CLUB: 5.90 (-0.07), RAX: 43.66 (+1.06), PTLA: 26.74 (-1.00), IPAR: 28.36 (-0.49), ATLS: 36.92 (+0.15), AMBC: 26.21 (-0.28), CUI: 7.19 (-0.58), PDLI: 7.92 (-0.10), OMER: 19.54 (-0.17), PRAA: 62.24 (-0.09), CARA: 8.13 (+0.05), HALO: 8.95 (-0.03), MODN: 10.45 (-0.05), CALL: 8.35 (-0.33), ASEI: 44.27 (-0.50), HGR: 21.04 (+0.33), ERII: 4.83 (unch)

Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.46 (+0.27), PCYC: 138.52 (+1.15), CLDX: 14.59 (-0.22), INCY: 71.72 (-0.15), BIND: 10.21 (+0.23), CELG: 107.67 (-0.58), OMER: 19.54 (-0.17), VSTM: 9.36 (-0.01), GILD: 105.00 (-1.90), OGXI: 2.13 (-0.05), ANTH: 1.84 (+0.02), NVAX: 5.31 (+0.07)

Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 202.47 (+1.96), PFE: 30.43 (+0.01), MRK: 59.53 (+0.22), AZN: 74.64 (+0.38), TEVA: 57.69 (-0.75), ITCI: 15.15 (-0.05), ABBV: 63.86 (+0.10), BMY: 57.87 (-0.74), OMER: 19.54 (-0.17)

Global Thrombotic Thrombocytopenic Purpura Therapeutics Pipeline Review 2014 - 6 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/thbpxv/thrombotic) has announced the addition of the "Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Thrombotic Thrombocytopenic Purpura, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Thrombotic Thrombocytopenic Purpura and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Ablynx NV - Kaketsuken K.K. - Glenmark Pharmaceuticals Ltd. - Octapharma AG - Archemix Corp. - Omeros Corporation Drug Profiles - plasma (human) - OMS-721 - caplacizumab - Recombinant Enzyme to Target ADAMTS-13 for Thrombotic Thrombocytopenic Purpura - GBR-600 - ARC-15105 For more information visit http://www.researchandmarkets.com/research/thbpxv/thrombotic
OMER: 19.54 (-0.17)

Omeros Announces Positive Data for MASP-2 Inhibitor in Experimental Model of Stroke
PR Newswire - Thu Nov 06, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced positive data using a derivative of OMS721 in a well-established animal model of stroke. OMS721 is the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2). MASP-2 is critical to the function of the lectin pathway, one of the principal components of the complement system, a key part of the immune response. Omeros controls the worldwide rights to MASP-2 inhibition and to all therapeutics targeting MASP-2.
OMER: 19.54 (-0.17)

Global Bipolar Disorder (Manic Depression) Therapeutics Pipeline Review, H2 2014 - 22 Companies & 30 Drug Profiles
M2 - Thu Nov 06, 3:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/6grxbp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Eli Lilly and Company - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Zogenix, Inc. - Richter Gedeon Nyrt. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Transition Therapeutics Inc. - Intas Pharmaceuticals Ltd. - D-Pharm Ltd. - Omeros Corporation - Intra-Cellular Therapies, Inc. - KemPharm, Inc. - Ascendis Pharma A/S - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - MarcoPolo Pharmaceuticals SA - Delpor, Inc. - Zysis Limited - Convergence Pharmaceuticals Ltd. - SK Biopharmaceuticals Co., Ltd. Drug Profiles - aripiprazole - quetiapine fumarate ER - ramelteon - ELND-005 - ziprasidone hydrochloride - cariprazine - YKP-3089 - Endoxifen - ITI-007 - DP-VPA - LY-2979165 - risperidone - Drug for Cancer and Neurodegenerative Disease - aripiprazole CR - lurasidone hydrochloride - SKL-PSY - Small Molecule To Antagonize GPR78 for Bipolar Disorder and Schizophrenia - NP-202 - ACP-005 - Small Molecule to Target GPR50 for CNS and Metabolic Disorders - risperidone - paliperidone - CNV-1061436 - PGW-5 - KP-303 - MP-03 - Small Molecules to Antagonize NMDA Receptor and CHRNA7 for CNS - Synthetic Peptides to inhibit IMPase for Bipolar Disorder - BRDK-98958073 - RP-5063 For more information visit http://www.researchandmarkets.com/research/6g...r_disorder
ZGNX: 1.32 (-0.01), PFE: 30.43 (+0.01), AZN: 74.64 (+0.38), TTHI: 6.42 (+0.03), TEVA: 57.70 (-0.74), ITCI: 15.15 (-0.05), LLY: 67.75 (+0.35), OMER: 19.54 (-0.17)

Omeros reports November 10
Seeking Alpha - at Seeking Alpha - Tue Nov 04, 10:53AM CST

OMER: 19.54 (-0.17)

Omeros Corporation to Announce Third Quarter 2014 Financial Results on November 10, 2014
PR Newswire - Tue Nov 04, 6:00AM CST
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, today announced that the company will issue its third quarter 2014 financial results for the period ended September 30, 2014, on Monday, November 10, 2014, after market close. Omeros management will host a conference call and webcast that day at 4:30 p.m. Eastern Time to discuss the financial results.
OMER: 19.54 (-0.17)

Nasdaq stocks posting largest percentage increases
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
IMDZ: 34.70 (+4.03), ABMD: 33.28 (-0.32), BGFV: 13.25 (-0.13), RDCM: 9.20 (-0.10), AMED: 25.32 (+0.21), MRCY: 13.46 (-0.17), OMER: 19.54 (-0.17), ESBF: 19.10 (-0.17), EVOK: 6.38 (+0.08), IQNT: 18.98 (+0.36), KONA: 22.82 (-0.19), TQNT: 22.44 (+0.34), LAKE: 11.55 (-0.69), SAJA: 6.21 (+0.31)

Why Omeros Corporation Stock Saw Big Gains
Sean Williams, The Motley Fool - Motley Fool - Thu Oct 30, 12:47PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Omeros , a biopharmaceutical company...
OMER: 19.54 (-0.17)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 11:47AM CDT

ABMD: 33.28 (-0.32), CALX: 10.95 (-0.12), LOJN: 2.64 (-0.04), ALU: 3.05 (-0.13), CDTI: 2.40 (+0.09), NKA: 4.84 (-0.04), ARAY: 7.06 (+0.01), GLUU: 3.67 (-0.03), PDII: 1.88 (-0.07), OMER: 19.54 (-0.17), ESBF: 19.10 (-0.17), CRNT: 1.15 (unch), CBDE: 0.84 (unch), PRXL: 56.46 (+0.26), BWEN: 6.55 (-0.10), ALDX: 7.91 (+0.39), BBSI: 21.78 (-1.01), LAKE: 11.55 (-0.69), OPHC: 0.99 (-0.01), WTW: 27.72 (+0.96)

Omidria(TM) Granted Pass-Through Reimbursement Status from CMS
PR Newswire - Thu Oct 30, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) announced today that it has received transitional pass-through status for its lead product Omidria(TM) (phenylephrine and ketorolac injection) 1%/0.3% from the Center for Medicare & Medicaid Services (CMS), the federal agency that administers the Medicare program. Approved earlier this year by the U.S. Food and Drug Administration (FDA) for use during cataract surgery or intraocular lens replacement (ILR), Omidria is the only FDA-approved product for intraocular administration that prevents intraoperative miosis (pupil constriction) and reduces postoperative pain, providing consistent and predictable management of these problems for ophthalmic surgeons and their patients. A large and growing market, cataract and other ILR procedures are among the most common surgical procedures performed in the U.S. with approximately four million expected in 2015.
OMER: 19.54 (-0.17)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 58

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 58

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 162

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 144

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 114

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Palantir: A Promising Investment Opportunity

Updated Category News Views 200

The Rise of Palantir Technologies Palantir Technologies (NYSE: PLTR) has emerged as a notable force in the stock market, especially in the field of artificial intelligence (AI). Known for its complex data analytics platforms, Palantir was founded after the September 11 attacks to offer essential software solutions to federal intelligence agencies, assisting them in...

Continue Reading
Castellum, Inc. Achieves Record Revenue and Debt Reduction

Updated Category News Views 176

Castellum, Inc. Reports Impressive Q2 Financial Results Castellum, Inc. (NYSE-American: CTM), a prominent player in cybersecurity, electronic warfare, and software services directed towards the federal government, recently unveiled its financial results for the second quarter of 2025. The results showcase a record revenue performance, enhanced operational efficiencies,...

Continue Reading
Revolutionary Ultra H2 Wheelset by Superteam Wheels Debuts

Updated Category News Views 441

Introducing the Ultra H2 Wheelset Superteam Wheels, a notable name in the cycling industry, has taken a major step forward with the launch of their Ultra H2 Special Edition Wheelset. This new product is set to redefine the standards of performance wheels, appealing to cycling enthusiasts who seek the perfect blend of speed, reliability, and design. Advanced Technology at...

Continue Reading
Family Care Center's IOP Secures Three-Year CARF Accreditation

Updated Category News Views 200

Family Care Center Achieves Notable CARF Accreditation Family Care Center, a prominent national provider in behavioral health care, has recently announced a significant milestone: its intensive outpatient program (IOP) has earned a coveted three-year accreditation from the Commission on Accreditation of Rehabilitation Facilities (CARF). This accomplishment not only...

Continue Reading
Entergy Boosts Quarterly Dividend to Support Shareholders

Updated Category News Views 169

Entergy Announces Dividend Increase for Shareholders Entergy's board of directors has recently made a significant decision to enhance shareholder value. They declared a quarterly dividend payment of $0.64 per share, marking a notable increase of $0.04 per share. This increment reflects the company's ongoing commitment to rewarding its investors. Dividend Payment Schedule...

Continue Reading